Literature DB >> 29329779

Receptor- and cellular compartment-specific activation of the cAMP/PKA pathway by α1-adrenergic and ETA endothelin receptors.

Ryan D Martin1, Yalin Sun1, Kyla Bourque1, Nicolas Audet1, Asuka Inoue2, Jason C Tanny3, Terence E Hébert4.   

Abstract

The signalling functions of many G protein-coupled receptors (GPCRs) expressed in the myocardium are incompletely understood. Among these are the endothelin receptor (ETR) family and α1-adrenergic receptor (α1-AR), which are thought to couple to the G protein Gαq. In this study, we used transcriptome analysis to compare the signalling networks downstream of these receptors in primary neonatal rat cardiomyocytes. This analysis indicated increased expression of target genes of cAMP responsive element modulator (CREM) after 24 h treatment with the α1-AR agonist phenylephrine, but not the ETR agonist endothelin-1, suggesting a specific role for the α1-AR in promoting cAMP production in cardiomyocytes. To validate the difference observed between these two GPCRs, we used heterologous expression of the receptors and genetically encoded biosensors in HEK 293 cell lines. We validated that both α1A- and α1B-AR subtypes were able to lead to the accumulation of cAMP in response to phenylephrine in both the nucleus and cytoplasm in a Gαs-dependent manner. However, the ETR subtype ETA did not affect cAMP levels in either compartment. All three receptors were coupled to Gαq signalling as expected. Further, we showed that activation of PKA in different compartments was α1-AR subtype specific, with α1B-AR able to activate PKA in the cytoplasm and nucleus and α1A-AR only able to in the nucleus. We provide evidence for a pathway downstream of the α1-AR, and show that distinct pools of a receptor lead to differential activation of downstream effector proteins dependent on their cellular compartment.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adrenergic receptors; Cardiac hypertrophy; Endothelin receptors; G protein-coupled receptors (GPCRs); Signal compartmentalization

Mesh:

Substances:

Year:  2018        PMID: 29329779     DOI: 10.1016/j.cellsig.2018.01.002

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  6 in total

1.  Differential Activation of P-TEFb Complexes in the Development of Cardiomyocyte Hypertrophy following Activation of Distinct G Protein-Coupled Receptors.

Authors:  Ryan D Martin; Yalin Sun; Sarah MacKinnon; Luca Cuccia; Viviane Pagé; Terence E Hébert; Jason C Tanny
Journal:  Mol Cell Biol       Date:  2020-06-29       Impact factor: 4.272

2.  Adreno-melatonin receptor complexes control ion homeostasis and intraocular pressure - their disruption contributes to hypertensive glaucoma.

Authors:  Hanan Awad Alkozi; Gemma Navarro; David Aguinaga; Irene Reyes-Resina; Juan Sanchez-Naves; Maria J Pérez de Lara; Rafael Franco; Jesus Pintor
Journal:  Br J Pharmacol       Date:  2020-02-26       Impact factor: 8.739

3.  Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells.

Authors:  Man Wu; Guanren Zhao; Xiaomei Zhuang; Tianhong Zhang; Ce Zhang; Wenpeng Zhang; Zhenqing Zhang
Journal:  Onco Targets Ther       Date:  2018-05-18       Impact factor: 4.147

4.  Signal profiling of the β1AR reveals coupling to novel signalling pathways and distinct phenotypic responses mediated by β1AR and β2AR.

Authors:  Viktoriya Lukasheva; Dominic Devost; Christian Le Gouill; Yoon Namkung; Ryan D Martin; Jean-Michel Longpré; Mohammad Amraei; Yuji Shinjo; Mireille Hogue; Monique Lagacé; Billy Breton; Junken Aoki; Jason C Tanny; Stéphane A Laporte; Graciela Pineyro; Asuka Inoue; Michel Bouvier; Terence E Hébert
Journal:  Sci Rep       Date:  2020-05-29       Impact factor: 4.379

Review 5.  Emerging Role of Compartmentalized G Protein-Coupled Receptor Signaling in the Cardiovascular Field.

Authors:  Bianca Plouffe; Alex R B Thomsen; Roshanak Irannejad
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-24

Review 6.  Update on GPCR-based targets for the development of novel antidepressants.

Authors:  Ioannis Mantas; Marcus Saarinen; Zhi-Qing David Xu; Per Svenningsson
Journal:  Mol Psychiatry       Date:  2021-02-15       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.